References

Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1 Parkin DM, Pisani P and FerlayJ (1999) Global cancer statistics. Ca Cancer J Clin 49(81): 33-64.

2 American Cancer Society (2000) What are the Key Statistics about Bladder Cancer? American Cancer Society. Internet Communication.

3 Sternberg CN and Swanson DA (1997) Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leibel SA, and Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven: Philadelphia, pp. 315-30.

4 Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6(2): 11326.

5 Sternberg C, Marini L, Calabro F and Scavina P (1999) Systemic chemotherapy ofbladder cancer. In: Skinner DG and Syrigos KN (eds) Bladder Cancer: biology and management. Oxford University Press: New York, pp. 299-315.

6 Sternberg CN, Yagoda A, Scher HI et al. (1989) M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 64: 244858.

7 Harker W, Meyers FJ, Freiha FS et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. J Clin Oncol 3: 1463-70.

8 Logothetis CJ, Samuels ML, Selig DE, Wallace S and Johnson DE (1985) Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumours. Cancer Treat Rep 69: 33-8.

9 Sternberg CN and Scher HI (1989) Management of invasive bladder neoplasms. In: Smith PH (ed.) Combination Therapy in Urological Malignacy. Springer-Verlag: London, pp. 95-118.

10 Sternberg CN, Yagoda A, Scher HI et al. (1985) Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumours. J Urol 133: 403-7.

11 Logothetis CJ, Dexeus F, Finn L et al. (1990) A prospective randomized trial comparing CISCA to M-VAC chemotherapy in advanced metastastic urothelial tumours. J Clin Oncol 8: 1050-5.

12 Dodd PM, McCaffrey JA, Herr H et al. (1999) Outcome of post-chemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Clin Oncol 17(8): 2546.

13 Loehrer P, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a Co-operative Group Study. J Clin Oncol 10: 106673.

14 Saxman SB, Propert KJ, Einhorn LH et al. (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a Co-operative Group Study. J Clin Oncol 15(7): 2564-9.

15 Calabro F and Sternberg CN (2002) New drugs and new approaches for the treatment of metastatic urothelial cancer. WorldJ Urol 20(3):158-66.

16 Calabro F amd Sternberg CN (2002) High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 12(5): 441-8.

17 Gabrilove JL,Jakubowski A, Scher H et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318: 1414-22.

18 Logothetis CJ, Dexeus FH, Sella A et al. (1990) Escalated therapy for refractory urothelial tumours: methotrexate, vinblastine, doxorubicin, cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82: 667-72.

19 Loehrer PJS, Elson P, Dreicer R et al. (1994) Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Co-operative Oncology Group trial. J Clin Oncol 12(3): 483-8.

20 Seidman AD, Scher HI, Gabrilove JL et al. (1992) Dose-intensification of methotrexate, vinblastine, doxorubicin and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 414-20.

21 Sternberg CN, de Mulder PHM, Schornagel JH et al. (2001) Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC)

chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic M-VAC in advanced urothelial tract tumours: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 19(10): 2638-46.

22 Sternberg CN (2000) Gemcitabine in bladder cancer. Sem Oncol 27(1)(suppl.2): 31-9.

23 Vogelzang NJ (2002) Future directions for gemcitabine in the treatment of genitourinary cancer. Sem Oncol 29(1suppl.3): 40-5.

24 Pollera CF, Ceribelli A, Crecco M and Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-4.

25 Gebbia V, Testa A, Borsellino N et al. (1999) Single agent 2', 2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 150(1): 11-15.

26 Stadler WM, Kuzel T, Roth B, Raghavan D and Dorr FA (1997) Phase II study of singleagent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15(11): 3394-8.

27 Moore MJ, Tannock IF, Ernst DS, Huan S and Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15(12): 3441-5.

28 Lorusso V, Pollera CF, Antimi M et al. (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34(8): 1208-12.

29 von der Maase H, Andersen L, Crino L, Weissbach L and Dogliotti L (1997) A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Amer Assoc Cancer Res 16: 324a.

30 Kaufman D, Stadler W, Carducci M et al. (1998) Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): final results of a phase II study. Proc Am Soc Clin Oncol 17: 320a (Abstract 1235).

31 Moore MJ, Winquist EW, Murray N et al. (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada trials group. J Clin Oncol 17(9): 2876-81.

32 Mancarella S, Lorusso V, Manzione L et al. (1999) Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial. Eur J Cancer 35(suppl.4): abstr 1405-347.

33 von der Maase H, Andersen L, Crino L, Weinknecht S and Dogliotti L (1999) Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10(12): 1461-5.

34 von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17): 3068-77.

35 Roth BJ, Dreicer R and Einhorn LH (1994) Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Co-operative Oncology Group. J Clin Oncol 12(11): 2264-70.

36 McCaffrey JA, Hilton S and Mazumdar M (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15(5): 1853-7.

37 de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J and Verweij J (1998) Docetaxel (taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy pre-treated patients. Br J Cancer 78(10): 1342-5.

38 Tu SM, Hossa E, Amato R, Kilbourn R and Logothetis CJ (1995) Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in treatmentof refractory urothelial malignancies. J Urol 154(5): 1719-22.

39 Burch PA, Richardson RL, Cha SS et al. (1999) Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC). Proc Am Soc Clin Oncol 18: 329a (Abstract 1266).

40 Dreicer R, Roth B, Lipsitz S, Cohen M, See W and Wilding G (1998) E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 17: 320a (Abstract 1233.

41 Pycha A, Grbovic M, Posch B, Heinz-Peer G, Schnack B and Zielinski ChMM (1999) Two years' experience with paclitaxel/carboplatin as first-line therapy in metastatic bladder cancer. J Urol Abstract: 263-1015.

42 Droz JP, Mottet N, Prapotrich D et al. (1998) Phase II study of taxol (paclitaxel) and carboplatin in patients with advanced transitional cell carcinoma of the urothelium: preliminary results. Proc Am Soc Clin Oncol 17: 316a (Abstract 1219.

43 Vaughn DJ, Malkowicz SB et al. (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regiment. J Clin Oncol 16(1): 255-60.

44 Small EJ, Lew D, Redman BG et al. (2000) Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial endpoint. J Clin Oncol 18(13): 2537-44.

45 Meyers FJ, Edelman MJ, Houston J and Lauder I (1998). Phase I/II trial of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 17: 317a (Abstract 1222).

46 Redman BG, Smith DC, Flaherty L, Du W and Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16(5): 18448.

47 Sengelov L, Kamby C, Lund B and Engelholm SA (1998) Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16(10): 3392-7.

48 Rothenberg ML, Sharma A, Weiss GR et al. (1998) Phase I trial ofpaclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumours. Ann Oncol 9(7): 7338.

49 Marini L, Sternberg CN, Sella A, Calabro F and van Rijn A (1999) A new regimen of gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 18: 346a (Abstract 1335).

50 Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S and Sella A (2001) Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12): 2993-8.

51 Meluch AA, Greco FA, Burris HA et al. (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19(12): 3018-24.

52 Parameswaran R, Fisch MJ, Ansari RH, Fox EP, Sweeney CJ and Einhorn LH (2001) A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Annu Meet Am Soc Clin Oncol 20(1): 200a. Ref Type: Abstract.

53 Guardino AE and Srinivas S (2001) Gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial malignancies. Proc Annu Meet Am Soc Clin Oncol 21(2): 150b. Ref Type: Abstract.

54 Fechner GH, Siener R, Reimann M et al. (2002) Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 167(4suppl.): 284. Ref Type: Abstract.

55 Kaufmann DS, Carducci MA, Kuzel T et al. (2002) Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multi-center phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Annu Meet Am Soc Clin Oncol 21(1): 192a. Ref Type: Abstract.

56 BellmuntJ, Guillem V et al. (2000) Phase I—II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 18(18): 3247-55.

57 Bellmunt J, de Wit R, Albiol S, Tabernero JM, Albanell J and Baselga J (2003) New drugs and new approaches in metastatic bladder cancer. J Clin Oncol (in press).

58 Hussain M, Vaishampayan U, Du W, Redman B and Smith DC (2001) Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19(9): 2527-33.

59 Bajorin DF, McCaffrey JA, Dodd PM et al. (2000) Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88(7): 1671-8.

60 Hussain M, Vaishampayan U and Smith DC (2002) Novel gemcitabine-containing triplets in the management of urothelial cancer. Sem Oncol 29(1suppl.3): 20-4.

61 Geller NL, Sternberg CN, Penenberg D, Scher H and Yagoda A (1991) Prognostic factors for survival of patients with advanced urothelial tumours treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy. Cancer 67: 1525-31.B

62 Bajorin DF, Dodd PM, Mazumdar M et al. (1999) Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17(10): 3173-81.

63 Stein JP, Grossfeld GD, Ginsberg DA et al. (1998) Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160(3Pt1): 645-59.

64 Cote RJ, Esrig D, Groshen S, Jones PA and Skinner DG (1997) P53 and treatment of bladder cancer. Nature 385(6612): 123-5.

65 Cote RJ, Dunn MD, Chatterjee SJ et al. (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has co-operative effects with p53. Cancer Res 58(6): 1090-4.

66 Sengelov L, Horn T and Steven K (1997) P53 nuclear immuno-reactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 123(10): 565-70.

67 Stein JP, Ginsberg DA, Grossfeld GD et al. (1998) Effect of p21 WAF1/CP1 expression on tumour progression in bladder cancer. J Natl Cancer Inst 90(14): 1072-9.

68 McCaffrey JA, Hilton S, Mazumdar M et al. (1997) Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrextae, vinblastine, doxorubicin and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 15(6): 2449-55.

69 McCaffrey J, Dodd PM, Hilton S et al. (1999) Ifosfamide and paclitaxel and cisplatin (ITP) chemotherapy for patients with unresectable or metastatic transitional cell carcinoma (TCC). Proc Am Soc Clin Oncol 18: 329a. Ref Type: Abstract.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment